REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of ...

How your immune system really ages — research shows aging brings adaptation not decline and reveals ways to maintain immune ...

Exposure to some bacteria, even while in utero, can be beneficial to developing a healthy immune system and reduce the risk ...

In type 1 diabetes, the body’s own immune system turns against the pancreas. Cells meant to protect you start destroying ...

You’ve worked extensively on respiratory syncytial virus (RSV) and influenza. What are the key differences in how the immune ...

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...

BioVaxys Technology and Sona Nanotech have signed a research agreement to develop cancer therapeutics utilising the former’s ...

Researchers identified a natural 'brake' within the innate immune system: the inhibitory receptor Siglec-E (SigE) and its human counterparts, Siglec-7 and Siglec-9. This receptor helps prevent ...

Current treatments to prevent organ transplant rejection focus mainly on suppressing T cells, part of the adaptive immune ...

BioVaxys Technology Corp. ( BioVaxys) and Sona Nanotech Inc. ( Sona) have entered a Research Agreement to develop new cancer ...

Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.

USask researchers recently published a paper in Scientific Reports that identified a promising alternative for controlling ...